查詢結果分析
相關文獻
- 第二期大腸癌病人開刀後存活分析:著眼於化學治療--單一醫學中心的經驗
- Adjuvant Chemotherapy for High-risk Stage II Colon Cancer
- 母兔產仔性狀之品種比較
- 非小細胞肺癌術前輔助性化學治療的經驗
- 不同飼糧纖維含量餵飼臺灣黑豬及藍瑞斯母豬對繁殖性能及仔豬育成之影響
- 紐西蘭白兔產仔性能與其在夏季之低落現象
- 成人低惡性度顱內星狀細胞瘤之術後放射治療
- The Role of Radiotherapy for Advanced Non-Small Cell Lung Cancer
- 應用存活分析法於員工流動率研究的探討
- 新母豬配種後30天內飼料攝食量和熱緊迫對於胚胎存活率等影響之研究
頁籤選單縮合
題名 | 第二期大腸癌病人開刀後存活分析:著眼於化學治療--單一醫學中心的經驗=Survival of Resectable Stage Ⅱ Colon Cancer Patients: Focus on Chemotherapy--Experience from a Single Institution |
---|---|
作者 | 劉惠文; 李興中; 宋詠娟; | 書刊名 | 臺灣癌症醫學雜誌 |
卷期 | 2:4 2015.12[民104.12] |
頁次 | 頁293-300 |
分類號 | 416.245 |
關鍵詞 | 第二期大腸癌; 存活率; 輔助性化學治療; 左右側大腸癌; Stage Ⅱ colon cancer; Overall survival; Adjuvant chemotherapy; Left and right side colon cancer; |
語文 | 中文(Chinese) |
中文摘要 | 背景:第二期大腸癌病人開刀後的輔助性化學治療目前尚無明確的定位,多以具高危險 因子之病患接受化療為目前共識,我們根據本院癌症資料庫回溯分析第二期大腸癌病人 治療狀況,進而得知輔助性化學治療的角色。 材料與方法:根據國泰綜合醫院癌症登記資料庫,癌症登記 2007 年至 2012 年病理期別 為第二期的大腸癌患者,共 176 名個案,統計總存活時間及各族群間存活比較。 結果:病人平均追蹤時間為 40.37 個月,第二期大腸癌是否接受術後輔助性化療的存活分 析,有接受化療之存活顯著較未接受化療者佳(p=0.003),三年存活率為 82%比上 61% (p=0.004),左側大腸癌接受化療之存活顯著較未接受化療者佳(HR 0.093,p=0.002), 男性接受化療之存活顯著較未接受化療者佳(HR 0.216,p=0.010)。 結論:根據本院資料庫分析,除了傳統共識中的高危險因子外,第二期左側大腸癌病人 可建議術後輔助性化學治療以改善存活時間。 |
英文摘要 | Background: Adjuvant chemotherapy for stage II resectable colon cancer has not been found to impact outcome. Most of the benefit of adjuvant therapy was seen in high-risk stage II disease. We analyzed the survival data from the cancer registry database of our institution to determine the efficacy of adjuvant chemotherapy in stage II colon cancer patients. Materials and Methods: From 2007 to 2012, 176 patients with resectable stage II colon cancer were treated at CGH. Overall survival (OS) analysis and sub-group analysis were performed. Results: Mean follow-up was 40.37 months. Survival of stage II colon cancer was superior in patients receiving adjuvant chemotherapy than in those without chemotherapy (p=0.003). Three-year OS was 82% vs. 61% (p=0.004). Survival was better in patients with left side colon cancer receiving chemotherapy (HR 0.093, p=0.002) and in male patients receiving chemotherapy (HR 0.216, p=0.010). Conclusions: Based on our study results, we recommend adjuvant chemotherapy in patients with stage II left side colon cancer in addition to in patients with high risk stage II colon cancer. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。